Cargando…

A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer

Prostate cancer ranks as the second most common malignancy in males. Prostate cancer progressing on androgen deprivation therapy (ADT) is castration-resistant prostate cancer (CRPC). Poly-ADP ribose polymerase (PARP) inhibitors (PARPis) have been at the forefront of the treatment of CRPC. We aim to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alameddine, Zakaria, Niazi, Muhammad Rafay Khan, Rajavel, Anisha, Behgal, Jai, Keesari, Praneeth Reddy, Araji, Ghada, Mustafa, Ahmad, Wei, Chapman, Jahangir, Abdullah, Terjanian, Terenig O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605202/ https://www.ncbi.nlm.nih.gov/pubmed/37887569 http://dx.doi.org/10.3390/curroncol30100669

Ejemplares similares

Rapidly Progressing Myelodysplastic Syndrome Initially Presenting as Acute Leukemia
por: Parylo, Sara, et al.
Publicado: (2017)

Correction: Rapidly Progressing Myelodysplastic Syndrome Initially Presenting as Acute Leukemia
por: Parylo, Sara, et al.
Publicado: (2017)

Role of Topotecan in Non-Small Cell Lung Cancer: A Review of Literature
por: Vennepureddy, Adarsh, et al.
Publicado: (2015)

Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma
por: Vennepureddy, Adarsh, et al.
Publicado: (2016)

Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA
por: Thumallapally, Nishitha, et al.
Publicado: (2017)

An Unusual Presentation of Nocardiosis in an Allogeneic Transplant Recipient
por: Ibrahim, Uroosa, et al.
Publicado: (2016)

Erratum to: Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA
por: Thumallapally, Nishitha, et al.
Publicado: (2017)

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
por: Thumallapally, Nishitha, et al.
Publicado: (2016)

A Repeat Case of Cefotetan-Induced Hemolytic Anemia in a Surgical Patient
por: Gallagher, Alayna, et al.
Publicado: (2022)

Development of Myelodysplastic Syndrome and Acute Myeloid Leukemia 15 Years after Hydroxyurea Use in a Patient with Sickle Cell Anemia
por: Baz, Walid, et al.
Publicado: (2012)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
por: Franza, A., et al.
Publicado: (2021)

Monoclonal Gammopathy of Undetermined Significance with Amyloid Deposition in the Lung and Non-Amyloid Eosinophilic Deposition in the Brain: A Case Report
por: Abi-Fadel, Francois, et al.
Publicado: (2010)

Telephone-based anticoagulation management in the homebound setting: a retrospective observational study
por: Hassan, Samer, et al.
Publicado: (2013)

An Unfortunate Case of Takotsubo Cardiomyopathy During Plasmapheresis for Myasthenia Crisis
por: Jahangir, Abdullah, et al.
Publicado: (2022)

A Case of COVID-19-Associated Autoimmune Hemolytic Anemia With Hyperferritinemia in an Immunocompetent Host
por: Huda, Zoha, et al.
Publicado: (2021)

The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer—A Systematic Literature Review with Application to the Canadian Context
por: Yanev, Ivan, et al.
Publicado: (2022)

Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy
por: Chen, Zheling, et al.
Publicado: (2021)

Methods for Evaluating the Efficacy of Medical Castration: A Systematic Review
por: Aguilar, Adriana, et al.
Publicado: (2023)

Oncological Response and Predictive Biomarkers for the Checkpoint Inhibitors in Castration-Resistant Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis
por: Fahmy, Omar, et al.
Publicado: (2021)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer
por: Gordon, Nicolas, et al.
Publicado: (2023)

Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wu, Kan, et al.
Publicado: (2021)

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

Recurrent acute-onset of chronic inflammatory demyelinating polyneuropathy after COVID-19 vaccination
por: Grantham, Tyler, et al.
Publicado: (2023)

PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?
por: Marchetti, Andrea, et al.
Publicado: (2022)

Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States
por: Xu, Chenxia, et al.
Publicado: (2022)

Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
por: Nogueira Costa, Inês, et al.
Publicado: (2022)

Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
por: Su, Christopher T., et al.
Publicado: (2022)

Comparison of normal saline solution with low-chloride solutions in renal transplants: a meta-analysis
por: Jahangir, Abdullah, et al.
Publicado: (2021)

Advances in PARP Inhibitors for Prostate Cancer
por: Tisseverasinghe, Steven, et al.
Publicado: (2023)

Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report
por: VanderWeele, David J., et al.
Publicado: (2015)

Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
por: Shore, Neal D., et al.
Publicado: (2021)

Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2023)

(177)Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: von Eyben, Finn E., et al.
Publicado: (2021)

Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials
por: Bowling, Gartrell C., et al.
Publicado: (2023)

Efficacy and Safety of Fevipiprant in Asthma: A Review and Meta-Analysis
por: Jahangir, Abdullah, et al.
Publicado: (2022)

Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis
por: Sun, Wanyi, et al.
Publicado: (2023)

The Association Between Gastroesophageal Reflux Disease and Non-Small Cell Lung Cancer: A Retrospective Case-Control Study
por: Amarnath, Shivantha, et al.
Publicado: (2022)

The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells
por: Morra, Francesco, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h9krg75tr3irql7n2l4b42mbja